e-learning
resources
Amsterdam 2015
Monday, 28.09.2015
Pulmonary hypertension: novel clinical insights
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Calculation of REVEAL scores for patients with PAH receiving riociguat in the PATENT-2 study
Raymond Benza (Pittsburgh, United States of America), Raymond Benza, Adaani Frost, Harrison Farber, Hossein-Ardeschir Ghofrani, Miguel Angel Gómez Sánchez, David Langleben, Stephan Rosenkranz, Dennis Busse, Christian Meier, Sylvia Nikkho, Marius Hoeper
Source:
International Congress 2015 – Pulmonary hypertension: novel clinical insights
Session:
Pulmonary hypertension: novel clinical insights
Session type:
Poster Discussion
Number:
2102
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Raymond Benza (Pittsburgh, United States of America), Raymond Benza, Adaani Frost, Harrison Farber, Hossein-Ardeschir Ghofrani, Miguel Angel Gómez Sánchez, David Langleben, Stephan Rosenkranz, Dennis Busse, Christian Meier, Sylvia Nikkho, Marius Hoeper. Calculation of REVEAL scores for patients with PAH receiving riociguat in the PATENT-2 study. Eur Respir J 2015; 46: Suppl. 59, 2102
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Change of right heart size and function by long-term therapy with riociguat in patients with PAH and CTEPH
Source: International Congress 2015 – Pulmonary hypertension: the right ventricle and its load
Year: 2015
Riociguat for the treatment of pulmonary hypertension: Safety data from the EXPERT registry
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016
Disease-targeted treatment improves cognitive function in patients with pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
Efficacy of riociguat in patients with inoperable CTEPH vs persistent/recurrent PH after pulmonary endarterectomy (PEA): Results from the phase III CHEST-1 study
Source: Annual Congress 2013 –Pulmonary circulation: treatment
Year: 2013
Item performance of the pulmonary arterial hypertension symptoms and impact (PAH-SYMPACT®) questionnaire: Results from the SYMPHONY study with macitentan
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016
Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i)
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study
Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots
Year: 2015
Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Riociguat in chronic thromboembolic pulmonary hypertension (CTEPH): ERS/ESC risk assessment in CHEST
Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension
Year: 2016
Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Year: 2013
Observational retrospective study on the treatment of pulmonary hypertension (PH) associated to pulmonary disease in patient with PH out of proportion
Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Year: 2013
Characteristics of idiopathic pulmonary arterial hypertension (IPAH) and PAH associated with connective tissue disease (APAH-CTD) patients in PROSPECT
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013
Characteristics of essential hypertension in COPD patients
Source: International Congress 2014 – COPD: points to ponder
Year: 2014
Effect of riociguat on pulmonary arterial compliance (PAC) in patients with PAH in PATENT-1
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
Acute and chronic effects of PDE5-Is on SpO2 in patients with COPD associated pulmonary hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Changes in inhalation therapy after combined assessment of COPD
Source: International Congress 2015 – COPD: exacerbations, gas exchange and associated dysfunction
Year: 2015
Riociguat in pulmonary arterial hypertension: ERS/ESC risk assessment in PATENT
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016
Severe pulmonary hypertension in patients with emphysema but preserved FEV1: Prognosis and response to treatment
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I
Year: 2013
Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease: A nationwide population-based study
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Pulmonary hypertension due to lung disease – Results from COMPERA
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept